Literature DB >> 15827279

Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.

J Soto1, J Toledo, J Vega, J Berman.   

Abstract

Two hundred twenty-six consecutive adult patients with cutaneous leishmaniasis in Colombia were treated with Glucantime and 81% were cured. The 19% who failed treatment had received a statistically significant lower total amount of antimony (354 mg/kg) than those who were cured (405 mg/kg) (P = 0.002). Thirty-nine of the failures were re-treated with Glucantime and 59% were cured. This large experience on initial and re-treatment cure rates probably represents the values found in clinical practice. In this series, parasite resistance may have been induced by the relatively low initial dose of antimony administered to some patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827279

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  IgG1 is pathogenic in Leishmania mexicana infection.

Authors:  Niansheng Chu; Bolaji N Thomas; Supriya R Patel; Laurence U Buxbaum
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

Review 2.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.

Authors:  Maria Claudia Barrera; Laura Jimena Rojas; Austin Weiss; Olga Fernandez; Diane McMahon-Pratt; Nancy G Saravia; Maria Adelaida Gomez
Journal:  Acta Trop       Date:  2017-08-24       Impact factor: 3.112

Review 4.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

5.  Profiles of Local and Systemic Inflammation in the Outcome of Treatment of Human Cutaneous Leishmaniasis Caused by Leishmania (Viannia).

Authors:  Adriana Navas; Olga Fernández; Carolina Gallego-Marín; María Del Mar Castro; Mariana Rosales-Chilama; Julieth Murillo; Alexandra Cossio; Diane McMahon-Pratt; Nancy Gore Saravia; María Adelaida Gómez
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

6.  FcgammaRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions.

Authors:  Bolaji N Thomas; Laurence U Buxbaum
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

7.  Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.

Authors:  Liliana López; Martha Robayo; Margarita Vargas; Iván D Vélez
Journal:  Trials       Date:  2012-05-17       Impact factor: 2.279

8.  Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection.

Authors:  Olga Lucía Fernández; Mariana Rosales-Chilama; Natali Quintero; Bruno L Travi; Dawn M Wetzel; María Adelaida Gómez; Nancy Gore Saravia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

9.  Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia).

Authors:  María Adelaida Gómez; Adriana Navas; Miguel Dario Prieto; Lina Giraldo-Parra; Alexandra Cossio; Neal Alexander; Nancy Gore Saravia
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 9.079

10.  Leishmania mexicana infection induces IgG to parasite surface glycoinositol phospholipids that can induce IL-10 in mice and humans.

Authors:  Laurence U Buxbaum
Journal:  PLoS Negl Trop Dis       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.